Synta Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 69
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S3E183FA407EN
Leaflet:

Download PDF Leaflet

Synta Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010
Synta Pharmaceuticals Corp. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Synta Pharmaceuticals Corp. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Synta Pharmaceuticals Corp. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Synta Pharmaceuticals Corp. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Synta Pharmaceuticals Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Synta Pharmaceuticals Corp.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Synta Pharmaceuticals Corp.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Synta Pharmaceuticals Corp. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Synta Pharmaceuticals Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Synta Pharmaceuticals Corp..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Synta Pharmaceuticals Corp. and identify potential opportunities in those areas.
Synta Pharmaceuticals Corp. Snapshot
Synta Pharmaceuticals Corp. Overview
Key Information
Key Facts
Synta Pharmaceuticals Corp. – Research and Development Overview
Key Therapeutic Areas
Synta Pharmaceuticals Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Synta Pharmaceuticals Corp. – Pipeline Products Glance
Synta Pharmaceuticals Corp. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Synta Pharmaceuticals Corp. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Synta Pharmaceuticals Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Synta Pharmaceuticals Corp. – Drug Profiles
Elesclomol
  Product Description
  Mechanism of Action
  R&D Progress
Elesclomol
  Product Description
  Mechanism of Action
  R&D Progress
Elesclomol + Docetaxel + Prednisone
  Product Description
  Mechanism of Action
  R&D Progress
Elesclomol Sodium + Taxotere
  Product Description
  Mechanism of Action
  R&D Progress
STA-5326
  Product Description
  Mechanism of Action
  R&D Progress
STA-9090
  Product Description
  Mechanism of Action
  R&D Progress
Elesclomol
  Product Description
  Mechanism of Action
  R&D Progress
STA-5312
  Product Description
  Mechanism of Action
  R&D Progress
STA-9090
  Product Description
  Mechanism of Action
  R&D Progress
STA-9090 + Docetaxel
  Product Description
  Mechanism of Action
  R&D Progress
CRACM Channel Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
STA-9584
  Product Description
  Mechanism of Action
  R&D Progress
Synta Pharmaceuticals Corp. – Pipeline Analysis
Synta Pharmaceuticals Corp. – Pipeline Products by Therapeutic Class
Synta Pharmaceuticals Corp. Pipeline Products By Target
Synta Pharmaceuticals Corp. – Pipeline Products by Route of Administration
Synta Pharmaceuticals Corp. – Pipeline Products by Molecule Type
Synta Pharmaceuticals Corp. – Recent Pipeline Updates
Synta Pharmaceuticals Corp. - Dormant Projects
Synta Pharmaceuticals Corp. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
STA-5326
Synta Pharmaceuticals Corp. – Company Statement
Synta Pharmaceuticals Corp. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 18, 2010: Synta Announces STA-9584 Recommended For $1 Million In DoD Funding For Study In Advanced Prostate Cancer
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
Sep 13, 2010: Synta Expands Phase II Trial For STA-9090 In Non-Small Cell Lung Cancer Based On Encouraging Clinical Activity
Aug 24, 2010: Synta Treats First Patient In Clinical Trial Of STA-9090 In Combination With Docetaxel In Solid Tumors
Jul 27, 2010: Synta Reports STA-9090 Demonstrates Potent In Vitro And In Vivo Activity In Acute Myeloid Leukemia
Jun 07, 2010: Synta Announces Encouraging STA-9090 Clinical Results Presented At ASCO
Jun 07, 2010: Synta Announces Encouraging STA-9090 Clinical Results Presented At ASCO
Financial Deals Landscape
Synta Pharmaceuticals Corp., Deals Volume Summary, 2004 to YTD 2010
Synta Pharmaceuticals Corp., Deals Summary By Region, 2004 to YTD 2010
Synta Pharmaceuticals Corp., Deals Summary, 2004 to YTD 2010
Synta Pharmaceuticals Corp. Detailed Deal Summary
Venture Financing
Synta Pharmaceuticals Raises $80 Million In Fouth Round Financing
Synta Pharmaceuticals Secures $50 Million In Series C Financing
Equity Offering
Synta Pharmaceuticals Announces Exercise Of Underwriter’s Over Allotment Option
Synta Pharmaceuticals Completes Initial Public Offering Of $50 Million
Synta Pharmaceuticals Completes Private Placement Of Series A Convertible Preferred Stock For $40 Million
Synta Pharmaceuticals Enters Into An Agreement With Roche
GlaxoSmithKline Enters Into An Agreement With Synta Pharmaceuticals
Synta Pharmaceuticals Terminates Agreement With GlaxoSmithKline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 69

LIST OF TABLES

Synta Pharmaceuticals Corp. – Pipeline by Therapy Area and Indication, 2010
Synta Pharmaceuticals Corp. – Pipeline by Stage of Development, 2010
Synta Pharmaceuticals Corp. – Monotherapy Products in Pipeline, 2010
Synta Pharmaceuticals Corp. – Combination Treatment Modalities in Pipeline, 2010
Synta Pharmaceuticals Corp. – Phase III, 2010
Synta Pharmaceuticals Corp. - Phase II, 2010
Synta Pharmaceuticals Corp. - Phase I, 2010
Synta Pharmaceuticals Corp. - Pipeline By Therapeutic Class, 2010
Synta Pharmaceuticals Corp. - Pipeline By Target, 2010
Synta Pharmaceuticals Corp. – Pipeline By Route of Administration, 2010
Synta Pharmaceuticals Corp. – Pipeline By Molecule Type, 2010
Synta Pharmaceuticals Corp. – Recent Pipeline Updates, 2010
Synta Pharmaceuticals Corp. - Dormant Developmental Projects, 2010
Synta Pharmaceuticals Corp. - Discontinued Pipeline Products, 2010
Synta Pharmaceuticals Corp., Deals Summary, 2004 to YTD 2010
Synta Pharmaceuticals Corp., Deals Summary by Region, 2004 to YTD 2010
Synta Pharmaceuticals Corp., Deals Summary, 2004 to YTD 2010
Synta Pharmaceuticals Raises $80 Million In Fouth Round Financing
Synta Pharmaceuticals Secures $50 Million In Series C Financing
Synta Pharmaceuticals Announces Exercise Of Underwriter’s Over Allotment Option
Synta Pharmaceuticals Completes Initial Public Offering Of $50 Million
Synta Pharmaceuticals Completes Private Placement Of Series A Convertible Preferred Stock For $40 Million
Synta Pharmaceuticals Enters Into An Agreement With Roche
GlaxoSmithKline Enters Into An Agreement With Synta Pharmaceuticals
Synta Pharmaceuticals Terminates Agreement With GlaxoSmithKline 67

LIST OF FIGURES

Synta Pharmaceuticals Corp. – Pipeline by Therapy Area and Indication, 2010
Synta Pharmaceuticals Corp. – Pipeline by Stage of Development, 2010
Synta Pharmaceuticals Corp. – Monotherapy Products in Pipeline, 2010
Synta Pharmaceuticals Corp. – Combination Treatment Modalities in Pipeline, 2010
Synta Pharmaceuticals Corp. – Pipeline By Therapeutic Class, 2010
Synta Pharmaceuticals Corp. - Pipeline By Target, 2010
Synta Pharmaceuticals Corp. – Pipeline By Route of Administration, 2010 36

Ask Your Question

Synta Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: